Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): A phase 3, randomised, double-blind, placebo-controlled trial

The Lancet Neurology

Volumn 10, Issue 12, 2011, Pages 1049-1057

  De Yebenes, Justo Garcia ^a   Landwehrmeyer, Bernhard ^b   Squitieri, Ferdinando ^c   Reilmann, Ralf ^d   Rosser, Anne ^e   Barker, Roger A ^f   Saft, Carsten ^g   Magnet, Markus K ^h   Sword, Alastair ⁱ   Rembratt, åsa ^j   Tedroff, Joakim ^k  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b UNIVERSITY OF ULM   (Germany)

^c IRCCS NEUROMED   (Italy)

^d UNIVERSITY OF MÜNSTER   (Germany)

^e CARDIFF UNIVERSITY   (United Kingdom)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^g ST JOSEF HOSPITAL   (Germany)

^h UNIVERSITY OF GRAZ   (Austria)

ⁱ Centum   (United Kingdom)

^j NEUROSEARCH A S   (Denmark)

^k NeuroSearch Sweden AB   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; HALOPERIDOL; OLANZAPINE; PLACEBO; PRIDOPIDINE; RISPERIDONE; SULPIRIDE; TIAPRIDE;

ADULT; ARTICLE; CAG REPEAT; CHOREA; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSTONIA; EYE MOVEMENT; FALLING; FATIGUE; FEMALE; GAIT; HAND MOVEMENT; HUMAN; HUNTINGTON CHOREA; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MOTOR PERFORMANCE; MOTOR SCORE; NAUSEA; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RHINOPHARYNGITIS; SCORING SYSTEM; SIDE EFFECT; SUBARACHNOID HEMORRHAGE; TREATMENT OUTCOME; UNIFIED HUNTINGTON DISEASE RATING SCALE;

ADULT; AGED; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HUNTINGTON DISEASE; MALE; MIDDLE AGED; MOTOR ACTIVITY; PIPERIDINES; TREATMENT OUTCOME;

EID: 81255195330     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(11)70233-2     Document Type: Article

References (32)

1. Walker FO Huntington's disease. Lancet 2007, 369:218-228.
2. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993, 72:971-983. The Huntington's Disease Collaborative Research Group.
3. Rosas HD, Salat DH, Lee SY, et al. Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity. Brain 2008, 131:1057-1068.
4. Heinsen H, Rub U, Bauer M, et al. Nerve cell loss in the thalamic mediodorsal nucleus in Huntington's disease. Acta Neuropathol 1999, 97:613-622.
5. Feigin A, Tang C, Ma Y, et al. Thalamic metabolism and symptom onset in preclinical Huntington's disease. Brain 2007, 130:2858-2867.
6. Oyanagi K, Takeda S, Takahashi H, Ohama E, Ikuta F A quantitative investigation of the substantia nigra in Huntington's disease. Ann Neurol 1989, 26:13-19.
7. Spargo E, Everall IP, Lantos PL Neuronal loss in the hippocampus in Huntington's disease: a comparison with HIV infection. J Neurol Neurosurg Psychiatry 1993, 56:487-491.
8. Ciarmiello A, Cannella M, Lastoria S, et al. Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington's disease. J Nucl Med 2006, 47:215-222.
9. Mahant N, McCusker EA, Byth K, Graham S Huntington's disease: clinical correlates of disability and progression. Neurology 2003, 61:1085-1092.
10. Rawlins M Huntington's disease out of the closet?. Lancet 2010, 376:1372-1373.
11. Spinney L Uncovering the true prevalence of Huntington's disease. Lancet Neurol 2010, 9:760-761.
12. Mestre T, Ferreira J, Coelho MM, Rosa M, Sampaio C Therapeutic interventions for symptomatic treatment in Huntington's disease. Cochrane Database Syst Rev 2009, 3. CD006456.
13. Burgunder J-M, Guttman M, Perlman S, et al. An international survey-based algorithm for the pharmacologic treatment of chorea in Huntington's disease. Plos Curr 2011, published online April 30. 10.1371/currents.RRN1260.
14. Andre VM, Cepeda C, Levine MS Dopamine and glutamate in Huntington's disease: a balancing act. CNS Neurosci Ther 2010, 16:163-178.
15. Seeman P, Tokita K, Matsumoto M, Matsuo A, Sasamata M, Miyata K The dopaminergic stabilizer ASP2314/ACR16 selectively interacts with D2 (High) receptors. Synapse 2009, 63:930-934.
16. Pettersson F, Ponten H, Waters N, Waters S, Sonesson C Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabilizer 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine (huntexil, pridopidine, ACR16). J Med Chem 2010, 53:2510-2520.
17. Ponten H, Kullingsjo J, Lagerkvist S, et al. In vivo pharmacology of the dopaminergic stabilizer pridopidine. Eur J Pharmacol 2010, 644:88-95.
18. Lundin A, Dietrichs E, Haghighi S, et al. Efficacy and safety of the dopaminergic stabilizer pridopidine (ACR16) in patients with Huntington's disease. Clin Neuropharmacol 2010, 33:260-264.
19. Unified Huntington's Disease Rating Scale: reliability and consistency. Mov Disord 1996, 11:136-142. Huntington Study Group.
20. 10 and remacemide in Huntington's disease. Neurology 2001, 57:397-404. Huntington Study Group.
21. Waters S, Tedroff J, Kieburtz K Validation of the modified motor score (mMS): a subscale of the Unified Huntington's Disease Rating Scale (UHDRS) motor score. Neurotherapeutics 2010, 7:144.
22. Waters S, Tedroff J, Waters N Correlations between functional measures, voluntary and involuntary motor symptoms in HD-multivariate analysis of cross-sectional and longitudinal REGISTRY data. J Neurol Neurosurg Psychiatry 2010, 81:A25-A26. European Huntington's Disease Network.
23. Guy W Clinical global impression (CGI). ECDEU assessment manual for psychopharmacology 1976, 218-222. US Department of Health, Education, and Welfare, Rockville, MD. W. Guy (Ed.).
24. Kieburtz K A randomized, double-blind, placebo-controlled trial of ACR16 in Huntington's disease. Neurotherapeutics 2011, 8:135. on behalf of the HSG HART study investigators.
25. Cersosimo MG, Raina GB, Piedimonte F, Antico J, Graff P, Micheli FE Pallidal surgery for the treatment of primary generalized dystonia: long-term follow-up. Clin Neurol Neurosurg 2008, 110:145-150.
26. Guide to clinical preventative services 1989, US Preventative Services Task Force, Diane Publishing, Darby, PA.
27. Ondo WG, Tintner R, Thomas M, Jankovic J Tetrabenazine treatment for Huntington's disease-associated chorea. Clin Neuropharmacol 2002, 25:300-302.
28. Dyhring T, Nielsen EO, Sonesson C, et al. The dopaminergic stabilizers pridopidine (ACR16) and (-)-OSU6162 display dopamine D(2) receptor antagonism and fast receptor dissociation properties. Eur J Pharmacol 2010, 628:19-26.
29. Pontén H, Carlsson A, Kullingsjö J, et al. The dopamine stabilizer ACR16 prevents L-DOPA induced sensitization in the 6-OHDA-lesioned rat. 32nd Annual Meeting, Society for Neuroscience; Orlando, FL, USA; Nov 2-7, 2002. Programme no 787.6 (abstr).
30. Penney JB, Young AB, Shoulson I, et al. Huntington's disease in Venezuela: 7 years of follow-up on symptomatic and asymptomatic individuals. Mov Disord 1990, 5:93-99.
31. Kloppel S, Draganski B, Golding CV, et al. White matter connections reflect changes in voluntary-guided saccades in pre-symptomatic Huntington's disease. Brain 2008, 131:196-204.
32. Marder K, Zhao H, Myers RH, et al. Rate of functional decline in Huntington's disease. Neurology 2000, 54:452-458.